SCHEMBL7525798

SCHEMBL7525798

CC1=NC(=Cc2[nH]c(-c3ccc(C)[nH]3)cc2OCc2ccccc2)C=C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.37
STAT3 P40763 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK1 P28482 3/20 0.35
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 2/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
CCNB1 P14635 1/20 0.33
CCND1 P24385 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
NTSR1 P30989 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7525791 1.00 HTT (0.37) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL7528992 0.89 MAPK1 (0.33) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL7528996 0.89 MAPK1 (0.33) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL7523062 0.87 HTT (0.37) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL7523057 0.87 HTT (0.37) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL7836219 0.85 EZH2 (0.45) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL7836215 0.85 EZH2 (0.45) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL7836187 0.82 EZH2 (0.37) HTTSTAT3SMN1; SMN2LMNAALDH1A1
SCHEMBL7836185 0.82 EZH2 (0.37) HTTSTAT3SMN1; SMN2LMNAALDH1A1
SCHEMBL7824735 0.81 EZH2 (0.36) HTTSTAT3SMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975592-B1 BENZYLOXY PRODIGIOSINE COMPOUNDS PHARMACIA & UPJOHN SPA (IT) 2002-06-05 EP claimed
US-20020049248-A1 Alone or in combination for treatment of adult-T-cell leukemia- lymphoma PHARMACIA & UPJOHN, SPA (IT) 2002-04-25 US claimed
US-6369096-B1 IMMUNOMODULATING AGENT, IMMUNOSUPPRESSANT PHARMACIA & UPJOHN S.P.A. (IT) 2002-04-09 US claimed
EP-0975592-B1 BENZYLOXY PRODIGIOSINE COMPOUNDS PHARMACIA & UPJOHN SPA (IT) 2002-06-05 EP disclosed
US-20020049248-A1 Alone or in combination for treatment of adult-T-cell leukemia- lymphoma PHARMACIA & UPJOHN, SPA (IT) 2002-04-25 US disclosed
US-6369096-B1 IMMUNOMODULATING AGENT, IMMUNOSUPPRESSANT PHARMACIA & UPJOHN S.P.A. (IT) 2002-04-09 US disclosed
EP-0975592-A1 BENZYLOXY PRODIGIOSINE COMPOUNDS PHARMACIA & UPJOHN S.p.A. (IT) 2000-02-02 EP disclosed
WO-1999040069-A1 BENZYLOXY PRODIGIOSINE COMPOUNDS PHARMACIA & UPJOHN S.P.A. (IT) 1999-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049248-A1 Alone or in combination for treatment of adult-T-cell leukemia- lymphoma MALT1, BCL6, CD4 HTT 3078/4885STAT3 263/4885SMN1; SMN2 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.